This website is intended exclusively for healthcare professionals and medical device manufacturers.
By accessing this site, you confirm that you belong to one of its of these categories and understand that the information provided is specifically intented for a professional audience.
"Overall growth remains strong, especially in emerging markets, fueled by biostimulators and GLP-1 companion treatments."
Medical Aesthetics are driven by sustainable, recession proof fundamental catalysts such as ageing demographics, urbanization and trend to ever younger onboarding of patients (prejuvenation trend). Aesthetics is no longer a vanity play: looking good is considered a basic human right by the upcoming generation, Gens Y and Z aspiring to self-transcendence and instant gratification, and the active senior, who also strive to ever increasing beauty standards. Aesthetics have democratized themselves as a status symbol in emerging markets, addictive and recurrent character of procedures once a certain regularity in the treatment protocol has been reached.
There is an explosion of versatility and creativity in combined offer with a proliferation of the number of medical aesthetics clinics and those providing holistic bundled procedures, or specializing themselves (hair and tatoo removal, hair regrowth, urogynaecological, aesthetic dentistry, wellness and longevity, anti-inflammageing and wellbeing).
Digitalization is also a major accelerator: connectivity to social networks and ubiquitous digitalization accelerate the uberization of an Instagrammable beauty. A hyper informed aesthetic consumer is prepared and no longer scared, more discerning than ever before. Intensification of telemedicine, telediagnostic, and telesurgery, as well as digital post-op monitoring, continues to grow. AI- and GenAI-augmented innovation is a key determinant of constant reinvention, empowered by the faster adoption of game-changing, disruptive technologies enabling painless procedures with a faster onset of action and no downtime — and by the advent of a new generation of HCPs.
Increased sophistication in safety, quality and efficiency requirements by HCPs and patients alike. Triumph of natural beauty in facial treatments without overcorrections, facial resurfacing, rhinoplasty, blepharoplasty, reshaping of the face, rejuvenation of the smile for women, masculinization of the face for millennials, hair restoration, prejuvenation and lunchtime procedures like mesotherapy and microneedling gain traction in Europe, China and MENA.
The gravitational pull of generative AI, the metaverse, machine learning and deep learning impacts aesthetics and the skincare vertical (dermatology, dermocosmetics, skincare) is the vanguard of new developments in medical beauty.
Body reshaping and tightening vulvovaginal treatments are gaining ground. Body sculpting treatments benefit from the trend of a “one-stop-shop holistic treatment” inviting patients to engage in immersive, pleasurable and gamified experiential journeys by combining energy based devices, picosecond laser or RF Microneedling with dermal fillers or post-op dermocosmetics and retargeting them with follow-up adjacent treatments, gifts on referrals, subscription systems and Buy Now Pay Later (BNPL scheme).
Global Medical Aesthetics Manufacturers’ revenues reached US$ 22.7bn in 2024 including Dermal Fillers based on HA and other biopolymers and skinboosters, such as PLLA, PDLA, PCL, CMC, CaHA, DMAE, as well as CaHA, Toxins, Regenerative Fillers and EBDs and are expected to reach US$ 31.3bn by 2029, eg.: a Compounded Annual Growth Rate of +7%, (Source BCG and GlobalData).
The segments of the dermal fillers, skin boosters, toxins and dermal fillers enjoy an even more sustainable dynamic with a CAGR of 11% over the period (2023 2033), (Sources: Spherical Insights, Mordor Intelligence and GlobalData.)
2023 has witnessed the emergence of biostimulators amplified in 2024 as a new category with a shift from HA-based crosslinked dermal fillers to bioactive treatments and tissular inductors with more subtle natural effects mimicking subtle natural healing while offering no-downtime, painless, and longer lasting effects by boosting tissue synthesis. The movement is led by skin boosters and innovative biostimulators or semi-permanent fillers based on PLLA, PDLA, PCL, CMC, CaHA, DMAE, as well as CaHA.
Expected to expand as a key entry product for considerers and first gateway into the aesthetics ecosystem for Millennials and GenZ pursuing a “prejuvenation trend” and capitalizing on a certain level of fillers’ fatigue.
The market for high-density dermal fillers used for lifting, redensification and retightening is fueled by the hype for GLP-1 agonist prescriptions (eg.: Ozempic, Wegowy) of the oral version Rybelsus (semaglutide). GLP-1 Agonists leading to “Ozempic prevention” or “Ozempic Face” treatments to correct or prevent lipodystrophies, deep wrinkles and muscle dislocation induced by such weight-loss treatments. Facial and body aesthetics are intertwined in a win win relationships: obese patients engage into GLP-1 treatments knowing that the effects can be corrected by parallel aesthetic treatments. As a result, 70% of Medical Aesthetics clinics in the US prescribe GLP 1 agonists, 43% in the UK and 32% in China (2024 BCG Medical Aesthetics Survey conducted over 4000 respondents).
Combination treatments associating dermal fillers, skin boosters or physician-dispensed skincare with such EBDs as minimally ablative lasers, Radiofrequency and Microneedling Devices, as well as HIFU or plasma-based and electrophoresis enable clinicians to leverage complementary synergies and foster a targeted delivery of skin regeneration fillers and growth factors or tissular inductors.
In 2024, the market reached $7.2bn (35% value, 19% volume), growing at 10% CAGR (2023–2033). 6.4m units (1ml eq.) sold, with 8.2m procedures, the world’s highest. Focus is on youthful, healthy looks, skin quality, and fitness, with strong emphasis on medical dedication and social media presence.
Valued at $1.1bn (4.9%) in 2024, with 9.6% CAGR. 3.5m units sold. A fast-adopting market for new regeneration and hair-growth solutions, driven by exosomes, microbiota, stem cells, and combined with EBD modalities.
At $0.4bn (1.9%) in 2024, with 7.2% CAGR and 0.9m units sold. Strong growth driven by high disposable income and openness to visible procedures (facial masculinization, lip densification, fuller cheeks, blepharoplasty, thread lifts).
Valued at $5.2bn (24% value, 18% volume) in 2024, with 9.3% CAGR. 4.5m units sold. Consumers favor natural, subtle rejuvenation and minimally invasive, holistic approaches (longevity clinics, cell reprogramming, microbiota, hormones). Social media plays a growing role, while doctor advertising remains banned in most countries.
Global leader with $7.7bn (36%) in 2024, rising at 11.1% CAGR. 20m units sold, including 4m procedures in China. Consumers (notably in India, China, Far East) aspire to timeless beauty through integrative facial rejuvenation, body–mind balance, biohacking, microbiota, and targeted treatments (blepharoplasty, rhinoplasty, skin brightening).
Overall growth remains strong, especially in emerging markets, fueled by biostimulators and GLP-1 companion treatments. However, consumer confidence and investments are hindered by market volatility, trade policy uncertainties, and tariff shifts.
